Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The product is supplied for subcutaneous administration in research models
If you vomit within 30 minutes of a tablet, it may not have been fully absorbed
Metsera has a portfolio of therapeutic candidates and combinations with four programs in clinical development and several next-generation programs with IND-enabling studies ongoing, aimed at addressing key unmet needs via fewer injections while achieving improved efficacy and tolerability
Tirzepatides dual-agonist profile suits incretin-focused research with extensive existing literature support
US$ 27.28
US$ 25.18
US$ 26.69
US$ 29.56
US$ 27.64
US$ 23.11
US$ 26.80
US$ 25.69
US$ 25.49
US$ 26.48
US$ 25.36
US$ 25.41
